Cancer and bone.

I. Introduction II. Normal Calcium and Bone Homeostasis A. Bone remodeling B. Calcium homeostasis C. Defenses against hyper- and hypocalcemia III. Humoral Mechanisms by Which Solid Tumors Affect the Skeleton A. Hypercalcemia B. Oncogenic osteomalacia C. Tumor lysis syndrome IV. Local Mechanisms by Which Tumors Affect the Skeleton A. Clinical manifestations B. Pathophysiology of the metastatic process to bone C. Local tumor syndromes in bone D. Therapy of tumor in bone

[1]  G. Mundy,et al.  Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. , 1985, Endocrinology.

[2]  I. Asahina,et al.  Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. , 1994, Growth factors.

[3]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[4]  B. O’Malley,et al.  An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Fallon,et al.  Oncogenic osteomalacia and inappropriate antidiuretic hormone secretion due to oat-cell carcinoma. , 1984, Annals of internal medicine.

[6]  M. Klagsbrun,et al.  Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. , 1986, The Journal of biological chemistry.

[7]  J. Potts,et al.  Production of parathyroid hormone by nonparthyroid tumors. , 1967, Journal of Clinical Endocrinology and Metabolism.

[8]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.

[9]  J. Kanis,et al.  Mechanism of malignant hypercalcaemia in carcinoma of the breast. , 1985, British medical journal.

[10]  S. Ralston,et al.  Cancer-Associated Hypercalcemia: Morbidity and Mortality: Clinical Experience in 126 Treated Patients , 1990 .

[11]  I. Franklin,et al.  Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion , 1991, British journal of haematology.

[12]  G. Rodan,et al.  Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. , 1988, Science.

[13]  R. Baron,et al.  Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. , 1982, The Journal of clinical endocrinology and metabolism.

[14]  J C Lucklider.  State of the art and the prospects for data gathering, storage, transformation, and retrieval. , 1966, Science.

[15]  L. Bonewald,et al.  Interleukin‐1 receptor antagonist inhibits the hypercalcemia mediated by interleukin‐1 , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  D. Banville,et al.  Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. , 1991, The Journal of clinical investigation.

[17]  B. Katzenellenbogen,et al.  Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. , 1994, Cancer research.

[18]  G. Strewler,et al.  Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. , 1987, The Journal of clinical investigation.

[19]  S. Shain,et al.  Rat prostate cancer cell line-specific production and apparent secretion of heparin-binding growth factors. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[20]  A. F. Stewart,et al.  Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. , 1987, The Journal of biological chemistry.

[21]  D. Resnick,et al.  Plasma Cell Dyscrasia with Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes: The POEMS Syndrome REPORT ON TWO CASES AND A REVIEW OF THE LITERATURE , 1980, Medicine.

[22]  F. Spyratos,et al.  Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. , 1993, Cancer research.

[23]  S. Matsui,et al.  Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. , 1987, Cancer research.

[24]  E. Kawinski,et al.  Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. , 1993, Biochemical and biophysical research communications.

[25]  G. Chodak,et al.  Basic fibroblast growth factor in human prostate cancer cells. , 1992, Cancer research.

[26]  J. Adams,et al.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. , 1983, The Journal of clinical investigation.

[27]  M. Muenke,et al.  Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. , 1996, The New England journal of medicine.

[28]  L. Feun,et al.  Tumor Lysis Syndrome After Induction Chemotherapy in Small‐Cell Lung Carcinoma , 1990, American journal of clinical oncology.

[29]  H. Vloedgraven,et al.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.

[30]  E. Brown.  PTH secretion in vivo and in vitro. Regulation by calcium and other secretagogues. , 1982, Mineral and electrolyte metabolism.

[31]  H. Datta,et al.  Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. , 1992, Endocrinology.

[32]  J. Hayman,et al.  Parathyroid hormone‐related protein: Immunohistochemical localization in cancers and in normal skin , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  O. Niwa,et al.  Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. , 1993, Blood.

[34]  D. Ribatti,et al.  Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.

[35]  K. Kasono,et al.  Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. , 1989, Endocrinology.

[36]  J. Kanis,et al.  A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. , 1995, British Journal of Cancer.

[37]  G. Blackburn,et al.  Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  M. Pandian,et al.  Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. , 1992, Clinical chemistry.

[39]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[40]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[41]  J. Warwick,et al.  Parathyroid hormone related protein and skeletal morbidity in breast cancer. , 1992, European journal of cancer.

[42]  G. Rodan,et al.  Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. , 1988, The Journal of biological chemistry.

[43]  G. Roodman,et al.  Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo. , 1995, Endocrinology.

[44]  O. V. Batson.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES , 1940, Annals of surgery.

[45]  H. Jüppner,et al.  A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. , 1995, Science.

[46]  M. Sporn,et al.  Induction of transforming growth factor beta in hormonally treated human prostate cancer. , 1994, British Journal of Cancer.

[47]  Zuxiong Chen,et al.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.

[48]  G. Mundy,et al.  Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. , 1983, The New England journal of medicine.

[49]  R. Derynck,et al.  Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype , 1996, The Journal of cell biology.

[50]  B F Boyce,et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.

[51]  Y. Takuwa,et al.  Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra- and intracellular pools in osteoblastic cells. , 1989, The American journal of physiology.

[52]  U. Liberman,et al.  A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. , 1990, Molecular endocrinology.

[53]  L. Bonewald,et al.  Expression of human transforming growth factor α by chinese hamster ovarian tumors in nude mice causes hypercalcemia and increased osteoclastic bone resorption , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  M. Freeman,et al.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. , 1991, Science.

[55]  A. Arnold,et al.  Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. , 1990, The New England journal of medicine.

[56]  P. Meunier,et al.  Quantitative histology of myeloma‐induced bone changes , 1982, British journal of haematology.

[57]  A. Mazar,et al.  An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. , 1990, Biochemical and biophysical research communications.

[58]  Jane M. Moseley,et al.  Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? , 1993, Molecular and cellular endocrinology.

[59]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[60]  C. Croce,et al.  Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. , 1994, Cancer research.

[61]  R. Warrell,et al.  Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  I. Nabi,et al.  Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. , 1991, The Journal of biological chemistry.

[63]  A. F. Stewart,et al.  Hypercalcemia in breast cancer. Reassessment of the mechanism. , 1987, The American journal of medicine.

[64]  G. Mundy,et al.  Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha. , 1985, Science.

[65]  G. Mundy,et al.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[66]  F. Cabanillas,et al.  Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma , 1994, Annals of Internal Medicine.

[67]  A. Parfitt.  The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. , 1976, Metabolism: clinical and experimental.

[68]  J. A. Glatz,et al.  Dexamethasone regulation of parathyroid hormone-related protein (PTHrP) expression in a squamous cancer cell line , 1994, Molecular and Cellular Endocrinology.

[69]  H. Marquardt,et al.  Complete amino acid sequence of human transforming growth factor type beta 2. , 1987, The Journal of biological chemistry.

[70]  S. Ralston,et al.  Mineralisation defects with pamidronate therapy for Paget's disease , 1993, The Lancet.

[71]  H. Ishikawa,et al.  Homotypic cell aggregations of human myeloma cells with ICAM‐1 and LFA‐1 molecules , 1991, British journal of haematology.

[72]  M. Birch,et al.  Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects , 1995, Molecular and Cellular Endocrinology.

[73]  J. E. Loewenstein,et al.  Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. , 1995, The Western journal of medicine.

[74]  R. Hegele,et al.  Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. , 1995, The Journal of clinical endocrinology and metabolism.

[75]  E. Fuchs,et al.  Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Bonjour,et al.  Stimulation by parathyroid hormone‐related protein and transforming growth factor‐α of phosphate transport in osteoblast‐like cells , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  Z. Pausova,et al.  Insertion of an Alu sequence in the Ca(2+)-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. , 1995, American journal of human genetics.

[78]  R. Ray,et al.  Mithramycin blocks protein binding and function of the SV40 early promoter. , 1989, The Journal of clinical investigation.

[79]  G. Mundy,et al.  A murine model of human myeloma bone disease. , 1997, Bone.

[80]  V. Paspaliaris,et al.  Steroid regulation of parathyroid hormone-related protein expression and action in the rat uterus , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[81]  J. Dunn,et al.  Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-I-transformed lymphocytes. , 1986, The Journal of clinical investigation.

[82]  R. Mercier,et al.  Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in Hodgkin's disease. , 1988, The American journal of medicine.

[83]  R. Baron,et al.  Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation , 2005 .

[84]  T. Clemens,et al.  Mechanical stimuli induce vascular parathyroid hormone-related protein gene expression in vivo and in vitro. , 1994, Endocrinology.

[85]  C. McMurtry,et al.  Oncogenic Osteomalacia Associated with Metastatic Prostate Carcinoma: Case Report and Review of the Literature , 1993, Journal of the American Geriatrics Society.

[86]  P. Månsson,et al.  Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. , 1989, Cancer research.

[87]  J. Thrasher,et al.  Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. , 1996, The Journal of clinical endocrinology and metabolism.

[88]  K. Anderson,et al.  Characterization of adhesion molecules on human myeloma cell lines. , 1992, Blood.

[89]  P. Sismondi,et al.  Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary , 1994, Journal of clinical laboratory analysis.

[90]  J. A. Glatz,et al.  Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Molecular and cellular endocrinology, 92 (1993) 55–62 , 1993, Molecular and Cellular Endocrinology.

[91]  H. Vloedgraven,et al.  Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. , 1996, Cancer research.

[92]  P. O'Brien,et al.  Parathyroid hormone-related peptide in lactation and in umbilical cord blood. , 1990, Mayo Clinic proceedings.

[93]  P. Lansdorp,et al.  Production of interleukin-1 by bone marrow myeloma cells. , 1989, Blood.

[94]  R. Derynck,et al.  Human transforming growth factor-alpha stimulates bone resorption in vitro. , 1985, The Journal of clinical investigation.

[95]  T. Yoneda,et al.  A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. , 1992, Cancer research.

[96]  H. Oppermann,et al.  Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. , 1992, The Journal of biological chemistry.

[97]  T. Tammela,et al.  The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. , 1994, European journal of cancer.

[98]  J. Seidman,et al.  Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation , 1994, Nature Genetics.

[99]  B. Kennedy,et al.  MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS. , 1965, The New England journal of medicine.

[100]  K. Ikeda,et al.  Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. , 1994, The Journal of clinical endocrinology and metabolism.

[101]  F. Craig,et al.  Development of an in vivo model of human multiple myeloma bone disease. , 1996, Blood.

[102]  M. Holick,et al.  The role of sunlight in the cutaneous production of vitamin D3. , 1988, Annual review of nutrition.

[103]  R. Kremer,et al.  Parathyroid-hormone-related peptide in hematologic malignancies. , 1996, The American journal of medicine.

[104]  A. F. Stewart,et al.  Cell Type-specific Secretion of Parathyroid Hormone-related Protein via the Regulated versus the Constitutive Secretory Pathway(*) , 1995, The Journal of Biological Chemistry.

[105]  T. Bringman,et al.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. , 1987, The New England journal of medicine.

[106]  R. Derynck.  TGF-β-receptor-mediated signaling , 1994 .

[107]  H. Lodish,et al.  Expression cloning of an adenylate cyclase-coupled calcitonin receptor. , 1991, Science.

[108]  P. Ward,et al.  Chemotactic responses of tumor cells to products of resorbing bone. , 1979, Science.

[109]  J. Orloff,et al.  Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure. , 1993, Kidney international.

[110]  O. Niwa,et al.  Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. , 1995, Blood.

[111]  D. Thiebaud,et al.  Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. , 1990, Archives of internal medicine.

[112]  J. G. Hurst,et al.  Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. , 1978, Endocrinology.

[113]  B. Kemp,et al.  Parathyroid hormone-related protein of malignancy: active synthetic fragments. , 1987, Science.

[114]  G. Rodan,et al.  Type β transforming growth factor (TGFβ) regulation of alkaline phosphatase expression and other phenotype‐related mRNAs in osteoblastic rat osteosarcoma cells , 1987 .

[115]  J. Habener,et al.  Metabolism of parathyroid hormone: physiologic and clinical significance. , 1974, The American journal of medicine.

[116]  G. J. Strewler.  Familial benign hypocalciuric hypercalcemia--from the clinic to the calcium sensor. , 1994, Western Journal of Medicine.

[117]  Sakae Tanaka,et al.  Bcl-2 Lies Downstream of Parathyroid Hormone–related Peptide in a Signaling Pathway That Regulates Chondrocyte Maturation during Skeletal Development , 1997, The Journal of cell biology.

[118]  H. Kawashima,et al.  Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action. , 1982, The Journal of clinical investigation.

[119]  R. Kremer,et al.  Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro. , 1994, The American journal of physiology.

[120]  L. Perey,et al.  Treatment of tumor-induced osteolysis by APD. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[121]  T. Powles,et al.  Treatment of skeletal disease in breast cancer with clodronate. , 1991, Bone.

[122]  R. Warrell,et al.  Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. , 1984, The Journal of clinical investigation.

[123]  B. Kennedy,et al.  Mithramycin inhibition of ribonucleic acid synthesis. , 1966, Cancer research.

[124]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[125]  C. Galasko.  Mechanisms of bone destruction in the development of skeletal metastases , 1976, Nature.

[126]  E. Canalis,et al.  Insulin-like growth factor (IGF) I and retinoic acid induce the synthesis of IGF-binding protein 5 in rat osteoblastic cells. , 1995, Endocrinology.

[127]  M. Feinglos,et al.  Osteomalacia Due to 1α,25-Dihydroxycholecalciferol Deficiency: ASSOCIATION WITH A GIANT CELL TUMOR OF BONE , 1977 .

[128]  F. Habib,et al.  Stimulation of human prostate cancer cell lines by factors present in human osteoblast‐like cells but not in bone marrow , 1995, The Prostate.

[129]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[130]  K. Hruska,et al.  Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. , 1981, The Journal of clinical investigation.

[131]  G. Mundy,et al.  Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. , 1988, The Journal of clinical investigation.

[132]  Y. Takada,et al.  Induction of experimental bone metastasis in mice by transfection of integrin α4β1 into tumor cells , 1996 .

[133]  M. Econs,et al.  Tumor-induced osteomalacia--unveiling a new hormone. , 1994, The New England journal of medicine.

[134]  A. Shimada,et al.  Stimulation of calcium reabsorption observed in advanced breast cancer patients with hypercalcemia and multiple bone metastases. , 1985, Japanese journal of cancer research : Gann.

[135]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[136]  J. Wozney,et al.  Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells , 1994, The Prostate.

[137]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[138]  M. Noda.  Transcriptional regulation of osteocalcin production by transforming growth factor-beta in rat osteoblast-like cells. , 1989, Endocrinology.

[139]  R. Rizzoli,et al.  Effect of transforming growth factor-alpha and parathyroid hormone-related protein on phosphate transport in renal cells. , 1990, The American journal of physiology.

[140]  L. Duong,et al.  Concentrations of parathyroid hormone-related protein in rat milk change with duration of lactation and interval from previous suckling, but not with milk calcium. , 1992, Endocrinology.

[141]  D. Rowe,et al.  Collagen and collagen-derived fragments are chemotactic for tumor cells. , 1981, The Journal of clinical investigation.

[142]  S. Klahr,et al.  Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake. , 1976, The Journal of clinical investigation.

[143]  E. Canalis,et al.  Skeletal Growth Factors Regulate the Synthesis of Insulin-like Growth Factor Binding Protein-5 in Bone Cell Cultures (*) , 1995, The Journal of Biological Chemistry.

[144]  O. Tørring,et al.  Inhibition by human interleukin-1 alpha of parathyroid hormone-related peptide effects on renal calcium and phosphorus metabolism in the rat. , 1992, Endocrinology.

[145]  M. Freeman,et al.  Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[146]  K. Feingold,et al.  Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes. , 1995, Endocrinology.

[147]  T. Schilling,et al.  Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. , 1994, The Journal of clinical endocrinology and metabolism.

[148]  J. Russell,et al.  Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[149]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[150]  O. Bijvoet,et al.  Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[151]  J. Baker,et al.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) , 1993, Cell.

[152]  A. Lipton,et al.  Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study , 1994, Cancer.

[153]  A. Broadus,et al.  Stretch-induced parathyroid hormone-related peptide gene expression in the rat uterus. , 1992, The Journal of biological chemistry.

[154]  O. Clark,et al.  Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. , 1993, The Journal of clinical endocrinology and metabolism.

[155]  R Wieser,et al.  Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region , 1993, Molecular and cellular biology.

[156]  M. Holick,et al.  1,25-dihydroxycholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone. , 1981, Endocrinology.

[157]  P. Schein,et al.  Osteoblastic bone metastasis in Zollinger-Ellison syndrome. , 1976, Radiology.

[158]  D. Djakiew,et al.  Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone , 1996, The Prostate.

[159]  K. Kurth,et al.  Investigative Urology: Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted Into Nude Mice , 1995 .

[160]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[161]  I. Henderson,et al.  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. , 1993, The American journal of medicine.

[162]  V. Rohmer,et al.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[163]  R. Mccance.  Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. , 1947, The Quarterly journal of medicine.

[164]  J. Orloff,et al.  Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. , 1994, Endocrine reviews.

[165]  G. Rodan,et al.  Type beta transforming growth factor (TGF beta) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. , 1987, Journal of cellular physiology.

[166]  P. Lacor,et al.  Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells , 1991, British journal of haematology.

[167]  T. Bonner,et al.  Identification and Functional Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor (*) , 1995, The Journal of Biological Chemistry.

[168]  B. Lytton,et al.  The role of vertebral veins in the dissemination of prostatic carcinoma. , 1981, The Journal of urology.

[169]  T. Pope,et al.  Computed tomography of isolated osteoblastic colon metastases in the bony pelvis. , 1988, The Journal of computed tomography.

[170]  J. Silver,et al.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. , 1986, The Journal of clinical investigation.

[171]  G. Merlini,et al.  The clinical implications of monoclonal immunoglobulins. , 1986, Seminars in oncology.

[172]  G. Stoica,et al.  Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[173]  J. Wysolmerski,et al.  Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. , 1995, Development.

[174]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[175]  C. Luparello,et al.  Transforming growth factor‐β1, β2, and β3, urokinase and parathyroid hormone‐related peptide expression in 8701‐BC breast cancer cells and clones , 1993 .

[176]  F. D. Di Padova,et al.  Interleukin‐6 is produced by bone and modulated by parathyroid hormone , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[177]  J. Kanis,et al.  Bone and cancer: pathophysiology and treatment of metastases. , 1995, Bone.

[178]  R. Rizzoli,et al.  Effects of treatment of malignancy‐associated hypercalcemia on serum parathyroid hormone‐related protein , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[179]  T. Schilling,et al.  Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. , 1993, The Journal of clinical endocrinology and metabolism.

[180]  K. Kasono,et al.  Tumor necrosis factor type α (cachectin) stimulates mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2 , 1987 .

[181]  P. Burton,et al.  Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. , 1990, Biochemical and biophysical research communications.

[182]  R. Rizzoli,et al.  Effects of epidermal growth factor on parathyroid hormone‐related protein production by mammary epithelial cells , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[183]  A. Sasaki.  Multi-step inhibition of breast cancer metastasis to bone by a combination of bisphosphonate and TIMP-2. (口頭発表) , 1996 .

[184]  A. G. Jessiman,et al.  Hypercalcemia in Carcinoma of the Breast , 1963, Annals of surgery.

[185]  T. Yoneda,et al.  Mechanisms of preferential metastasis of breast cancer to bone - (Review). , 1996, International journal of oncology.

[186]  S. Nussbaum.  Pathophysiology and management of severe hypercalcemia. , 1993, Endocrinology and metabolism clinics of North America.

[187]  A. Gazdar,et al.  Glucocorticoid regulation of parathyroid hormone-related peptide gene transcription in a human neuroendocrine cell line. , 1989, Molecular endocrinology.

[188]  D. Ackery,et al.  Radionuclide-targeted therapy for the management of metastatic bone pain. , 1993, Seminars in oncology.

[189]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[190]  C. Leu,et al.  Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[191]  A. V. von Eschenbach,et al.  Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy , 1993, Cancer.

[192]  A. Mithal,et al.  The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. , 1996, Endocrine reviews.

[193]  H. Poulsen,et al.  Transforming growth factor and cancer , 1995 .

[194]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[195]  E. Diamandis,et al.  Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. , 1994, Clinical biochemistry.

[196]  D. Heath.  Parathyroid hormone related protein , 1993, Clinical endocrinology.

[197]  M. Minemura,et al.  Localization of basic fibroblast growth factor (bFGF) in a metastatic cell line (AT-3) established from the Dunning prostatic carcinoma of rat: application of a specific monoclonal antibody. , 1992, Advances in experimental medicine and biology.

[198]  R. Rubens,et al.  Hypercalcaemia and breast cancer--an increased humoral component in patients with liver metastases. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[199]  T. Chambers,et al.  Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.

[200]  G. Mundy,et al.  Expression of the BMP 2 gene during bone cell differentiation. , 1994, Critical reviews in eukaryotic gene expression.

[201]  D. Diep,et al.  High levels of a parathyroid hormone-like protein in milk. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[202]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[203]  M. Chapuy,et al.  Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia , 1983, Cancer.

[204]  D. S. Coffey.  Prostate cancer metastasis: Talking the walk , 1996, Nature Medicine.

[205]  B. Riggs,et al.  Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. , 1974, The Journal of clinical investigation.

[206]  A. F. Stewart,et al.  Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.

[207]  T. Powles,et al.  The Inhibition by Aspirin and Indomethacin of Osteolytic Tumour Deposits and Hypercalcaemia in Rats with Walker Tumour, and its Possible Application to Human Breast Cancer , 1973, British Journal of Cancer.

[208]  G. Mundy,et al.  Bone-resorbing activity in supernatants from lymphoid cell lines. , 1974, The New England journal of medicine.

[209]  S. Ralston,et al.  Breast Cancer-Associated Hypercalcaemia: A Reassessment of Renal Calcium and Phosphate Handling , 1990, Annals of clinical biochemistry.

[210]  M. Fukase,et al.  Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. , 1988, The Journal of clinical endocrinology and metabolism.

[211]  E. Barrack,et al.  Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. , 1995, Cancer research.

[212]  J. Oesterling,et al.  Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. , 1993, The Urologic clinics of North America.

[213]  R. MacIsaac,et al.  Parathyroid hormone‐related protein: a possible endocrine function in lactation , 1992, Clinical endocrinology.

[214]  A. Hata,et al.  TGF-β signalling through the Smad pathway , 1997 .

[215]  Clifford J. Tabin,et al.  Regulation of Rate of Cartilage Differentiation by Indian Hedgehog and PTH-Related Protein , 1996, Science.

[216]  S. Rabbani,et al.  Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC‐3 , 1995, The Prostate.

[217]  S. Kitazawa,et al.  Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. , 1993, The American journal of pathology.

[218]  C. Polychronakos,et al.  Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. , 1993, Anticancer research.

[219]  H. Poulsen,et al.  Transforming growth factor beta and cancer. , 1995, Cancer treatment reviews.

[220]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[221]  G. Powell,et al.  Localization of parathyroid hormone‐related protein mrna expression in breast cancer and metastatic lesions by in situ hybridization , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[222]  N. Bell.  Vitamin D-endocrine system. , 1985, The Journal of clinical investigation.

[223]  E. Nemeth,et al.  The calcium receptor and familial benign hypocalciuric hypercalcemia , 1995 .

[224]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[225]  M. Feinglos,et al.  Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. , 1977, The Journal of clinical investigation.

[226]  J. George,et al.  Metastatic cervical carcinoma presenting as psoas abscess and osteoblastic and lytic bony metastases. , 1995, Singapore medical journal.

[227]  M. Pollard,et al.  Effects of diphosphonate and X‐Rays on bone lesions induced in rats by prostate cancer cells , 1988, Cancer.

[228]  T. Clemens,et al.  Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. , 1987, Science.

[229]  H. Kawashima,et al.  Metabolic Acidosis Suppresses 25-Hydroxyvitamin D3-1α-Hydroxylase in the Rat Kidney: DISTINCT SITE AND MECHANISM OF ACTION , 1982 .

[230]  G. Gualdi,et al.  Diffuse leptomeningeal gliomatosis with osteoblastic metastases and no evidence of intraaxial lesions. , 1995, AJNR. American journal of neuroradiology.

[231]  H. Jüppner,et al.  Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84) , 1995, Endocrinology.

[232]  H. DeLuca,et al.  Metabolism and mechanism of action of vitamin D. , 1976, Annual review of biochemistry.

[233]  N. Bundred,et al.  Parathyroid hormone‐related protein (PTHrP) gene expression in solid tumours associated with normocalcaemia and hypercalcaemia , 1993, The Journal of pathology.

[234]  M. Steiner,et al.  Expression of transforming growth factor-beta 1 in prostate cancer. , 1994, Endocrinology.

[235]  J. Hayman,et al.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.

[236]  L. Raisz,et al.  Responses of fetal rat bone to thyrocalcitonin in tissue culture. , 1968, Endocrinology.

[237]  G. Mundy,et al.  Direct resorption of bone by human breast cancer cells in vitro , 1978, Nature.

[238]  T. Martin,et al.  The hypercalcemia of malignancy: pathogenesis and management. , 1982, Metabolism: clinical and experimental.

[239]  K. Feingold,et al.  Cytokine regulation of parathyroid hormone-related protein messenger ribonucleic acid levels in mouse spleen: paradoxical effects of interferon-gamma and interleukin-4. , 1994, Endocrinology.

[240]  K. Feingold,et al.  Endotoxin increases parathyroid hormone-related protein mRNA levels in mouse spleen. Mediation by tumor necrosis factor. , 1993, The Journal of clinical investigation.

[241]  R. V. van Oers,et al.  Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. , 1994, Blood.

[242]  J. Orloff,et al.  Defining the roles of parathyroid hormone-related protein in normal physiology. , 1996, Physiological reviews.

[243]  M. K. Mclennan.  Case report 657: Malignant epithelial thymoma with osteoplastic metastases. , 1991, Skeletal radiology.

[244]  R. Mason,et al.  Vitamin D conversion by sarcoid lymph node homogenate. , 1984, Annals of internal medicine.

[245]  T. Clemens,et al.  Abundant expression of parathyroid hormone-related protein in primary rat aortic smooth muscle cells accompanies serum-induced proliferation. , 1991, The Journal of clinical investigation.

[246]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[247]  W. Ratcliffe.  Role of parathyroid hormone‐related protein in lactation , 1992, Clinical endocrinology.

[248]  M. Noda,et al.  In vivo stimulation of bone formation by transforming growth factor-beta. , 1989, Endocrinology.

[249]  A. F. Stewart,et al.  Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. , 1985, The Journal of clinical endocrinology and metabolism.

[250]  E. Chen,et al.  A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.

[251]  S. S. Alison.  26. Ossified Gall-Bladder , 1845 .

[252]  A. F. Stewart,et al.  Immunoaffinity purification of parathyroid hormone‐related protein from bovine milk and human keratinocyte‐conditioned medium , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[253]  K. Miyazono,et al.  Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. , 1988, The Journal of biological chemistry.

[254]  E. Canalis.  Skeletal growth factors and aging. , 1994, The Journal of clinical endocrinology and metabolism.

[255]  野田 政樹.  Transcriptional regulation of osteocalcin production by transfoming growth factor-β in rat osteoblast-like cells , 1992 .

[256]  E. Mackie,et al.  Stimulation of bone formation in vivo by transforming growth factor-beta: remodeling of woven bone and lack of inhibition by indomethacin. , 1990, Bone.

[257]  C. Cooper,et al.  Effect of endogenously produced parathyroid hormone-related peptide on growth of a human hepatoma cell line (Hep G2). , 1996, Endocrinology.

[258]  B. O’Malley,et al.  Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. , 1988, Science.

[259]  H. F. Barker,et al.  Expression of adhesion molecules LFA‐3 and N‐CAM on normal and malignant human plasma cells , 1992, British journal of haematology.

[260]  M. Zaidi,et al.  Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin. , 1992, The Journal of endocrinology.

[261]  A. Boyde,et al.  Scanning electron microscopy in bone pathology: review of methods, potential and applications. , 1986, Scanning electron microscopy.

[262]  T. Clemens,et al.  Angiotensin II regulates parathyroid hormone-related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. , 1993, The Journal of biological chemistry.

[263]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[264]  S. Özsoylu.  Vitamin D-dependent rickets. , 1985 .

[265]  M. Sporn,et al.  Some recent advances in the chemistry and biology of transforming growth factor-beta , 1987, The Journal of cell biology.

[266]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[267]  T. Martin,et al.  Hypercalcemia in pregnancy and lactation associated with parathyroid hormone-related protein. , 1993, The New England journal of medicine.

[268]  E. Hendler,et al.  Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. , 1984, The New England journal of medicine.

[269]  R. Warrell,et al.  Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. , 1988, Annals of internal medicine.

[270]  R. Warrell,et al.  Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. , 1990, The New England journal of medicine.

[271]  A. Howell,et al.  Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. , 1988, BMJ.

[272]  D. Drucker,et al.  Parathyroid hormone-related peptide is a downstream target for ras and src activation. , 1994, The Journal of biological chemistry.

[273]  M. Nesbit,et al.  Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. , 1973, The New England journal of medicine.

[274]  J A Kanis,et al.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. , 1994, Bone.

[275]  J. Foley,et al.  Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. , 1996, Cancer research.

[276]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[277]  G. Mundy,et al.  Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. , 1996, Cancer research.

[278]  K. Inoue,et al.  [Hypercalcemia in breast cancer]. , 1984, Gan to kagaku ryoho. Cancer & chemotherapy.

[279]  M. Rosenblum,et al.  Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma , 1994 .

[280]  G. Mundy,et al.  Evidence for the secretion of an osteoclast stimulating factor in myeloma. , 1974, The New England journal of medicine.

[281]  G. Mundy,et al.  Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. , 1993, The Journal of clinical endocrinology and metabolism.

[282]  J. Zerwekh,et al.  Human placental production of 1 alpha,25-dihydroxyvitamin D3: biochemical characterization and production in normal subjects and patients with pseudohypoparathyroidism. , 1986, The Journal of clinical endocrinology and metabolism.

[283]  K. Watt,et al.  Human prostate-specific antigen: structural and functional similarity with serine proteases. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[284]  A. F. Stewart,et al.  Glycosylation of parathyroid hormone-related peptide secreted by human epidermal keratinocytes. , 1991, The Journal of clinical endocrinology and metabolism.

[285]  A. Howell,et al.  Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. , 1994, British Journal of Cancer.

[286]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[287]  R. Eastell,et al.  Metabolic effects of pamidronate in patients with metastatic bone disease. , 1996, British Journal of Cancer.

[288]  L. Suva,et al.  Parathyroid hormone-related protein purified from a human lung cancer cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[289]  S. Christakos,et al.  Primer on the metabolic bone diseases and disorders of mineral metabolism , 1994 .

[290]  J. Massagué,et al.  Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. , 1987, The Journal of biological chemistry.

[291]  J. Oesterling,et al.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.

[292]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[293]  R. Derynck.  TGF-beta-receptor-mediated signaling. , 1994, Trends in biochemical sciences.

[294]  T. Martin,et al.  Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. , 1993, Leukemia.

[295]  L. Orci,et al.  The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins). , 1982, Endocrine reviews.

[296]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[297]  P. Delmas.  Bisphosphonates in the treatment of bone diseases. , 1996, The New England journal of medicine.

[298]  G. Segre,et al.  Characteristics of bovine parathyroid hormone extraction by dog liver in vivo. , 1981, The American journal of physiology.

[299]  G. Roodman,et al.  Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. , 1997, Cancer research.

[300]  T. Rosol,et al.  Effects of transforming growth factor-beta on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro. , 1994, Endocrinology.

[301]  J. Bonjour,et al.  A thymoma as a cause of true ectopic hyperparathyroidism. , 1994, The Journal of clinical endocrinology and metabolism.

[302]  J. Jaspan,et al.  Case report: clinical hypocalcemia: the endocrine conference of the Alton Ochsner Medical Institutions and Tulane University Medical Center. , 1994, The American journal of the medical sciences.

[303]  A. Sasaki.  Parathyroid hormone-related protein(PTHrP) expression by breast cancer cells enhance osteolytic bone metastases in vivo. (口頭発表) , 1994 .

[304]  A. Aaron.  The management of cancer metastatic to bone. , 1994, JAMA.

[305]  M. Glimcher,et al.  Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.

[306]  T. Masaki,et al.  The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. , 1990, Biochemical and biophysical research communications.

[307]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[308]  J. Seidman,et al.  Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism , 1993, Cell.

[309]  P. Delmas,et al.  Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. , 1986, The Journal of clinical investigation.

[310]  T. Yoneda,et al.  The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. , 1993, The Journal of clinical endocrinology and metabolism.

[311]  S. Wimalawansa.  Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy , 1994, Clinical endocrinology.

[312]  O. Niwa,et al.  Expression of CD 21 Antigen on Myeloma Cells and its Involvement in Their Adhesion to Bone Marrow Stromal Cells , 2000 .

[313]  R. Derynck,et al.  Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[314]  A. F. Stewart,et al.  Preliminary characterization of circulating amino- and carboxy-terminal fragments of parathyroid hormone-related peptide in humoral hypercalcemia of malignancy. , 1992, The Journal of clinical endocrinology and metabolism.

[315]  D. F. Preston,et al.  Strontium 89 therapy for the palliation of pain due to osseous metastases. , 1995, JAMA.

[316]  D. Drucker,et al.  Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. , 1990, The Journal of clinical endocrinology and metabolism.

[317]  E. Jimi,et al.  Basic fibroblast growth factor inhibits osteoclast‐like cell formation , 1996, Journal of cellular physiology.

[318]  E. Canalis,et al.  Bone morphogenetic protein-2 inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures. , 1995, Endocrinology.

[319]  R. Recker,et al.  Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study , 1991 .

[320]  C. Galasko,et al.  Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins , 1976, Nature.

[321]  L. Bonewald,et al.  Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[322]  G. Mundy,et al.  Bone remodeling and its disorders , 1999 .

[323]  C. Gennari,et al.  Osteoblastic metastases from carcinoid tumor. , 1994, Clinical and experimental rheumatology.

[324]  L. Bonewald,et al.  Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long‐term cultures of fetal rat calvarial osteoblasts , 1994 .

[325]  S. Mohan,et al.  Bone growth factors. , 1991, Clinical orthopaedics and related research.

[326]  T. Martin,et al.  Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. , 1991, The Journal of clinical endocrinology and metabolism.

[327]  J. Wozney,et al.  Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulates BMP-2 mRNA expression and BMP-2 promoter activity in primary fetal rat calvarial osteoblast cultures , 1995 .

[328]  B. Riggs,et al.  Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. , 1974, The American journal of medicine.

[329]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[330]  L. Aarden,et al.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. , 1996, The Journal of clinical investigation.

[331]  A. Howell,et al.  Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. , 1991, European journal of cancer.

[332]  D. Barnes,et al.  TGF alpha and TGF beta expression in mammary carcinoma , 1993, The Journal of pathology.

[333]  J. Heersche,et al.  Calcitonin and the formation of 3',5'-AMP in bone and kidney. , 1974, Endocrinology.

[334]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[335]  J. Foekens,et al.  Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.

[336]  G. Mundy,et al.  Altered renal calcium handling in hypercalcemia of malignancy. , 1991, Journal of the American Society of Nephrology : JASN.

[337]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[338]  A. F. Stewart,et al.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. , 1980, The New England journal of medicine.

[339]  G. Mundy,et al.  Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. , 1978, The American journal of medicine.

[340]  Y. Park,et al.  Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions. , 1994, Journal of Korean medical science.

[341]  G. Mundy,et al.  Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. , 1991, Endocrinology.

[342]  S. Ralston,et al.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. , 1986, British medical journal.

[343]  P. Kao,et al.  Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. , 1994, The New England journal of medicine.

[344]  L. Witters,et al.  Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes. , 1981, The Journal of clinical investigation.

[345]  M. Loda,et al.  Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer , 1996, Nature Medicine.

[346]  A. Parfitt.  Bone and plasma calcium homeostasis. , 1987, Bone.

[347]  A. Sommer,et al.  Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. , 1994, Growth regulation.

[348]  J. Pickren,et al.  Metastases from carcinoma of mammary gland: An autopsy study , 1979, Journal of surgical oncology.

[349]  E. Frenkel,et al.  Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. , 1984, Annals of internal medicine.

[350]  D. Tindall,et al.  Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. , 1995, The Journal of clinical endocrinology and metabolism.

[351]  M. Koutsilieris,et al.  Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. , 1987, The Journal of clinical investigation.

[352]  D. Bertolini,et al.  Bone destruction and hypercalcemia in plasma cell myeloma. , 1986, Seminars in oncology.

[353]  J. Santibañez,et al.  Prostate‐derived soluble factors block osteoblast differentiation in culture , 1996, Journal of cellular biochemistry.

[354]  P. Barrett,et al.  Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line. , 1988, The Journal of clinical endocrinology and metabolism.

[355]  G. Segre,et al.  Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. , 1981, The Journal of clinical investigation.

[356]  A. Parfitt,et al.  Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. , 1996, The New England journal of medicine.

[357]  G. Mundy,et al.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. , 1980, Annals of internal medicine.

[358]  G. Mundy,et al.  Sequence and expression of bone morphogenetic protein 3 mRNA in prolonged cultures of fetal rat calvarial osteoblasts and in rat prostate adenocarcinoma PA III cells. , 1995, DNA and cell biology.

[359]  A. F. Stewart,et al.  Overexpression of Parathyroid Hormone-related Protein in the Pancreatic Islets of Transgenic Mice Causes Islet Hyperplasia, Hyperinsulinemia, and Hypoglycemia (*) , 1996, The Journal of Biological Chemistry.

[360]  P. Burton,et al.  Parathyroid hormone‐related peptide can regulate the growth of human lung cancer cells, and may form part of an autocrine TGF‐α loop , 1992 .

[361]  Bin Liu,et al.  Inhibition of processing of parathyroid hormone‐related peptide by anti‐sense furin: Effect in vitro and in vivo on rat leydig (H‐500) tumor cells , 1995, International journal of cancer.

[362]  G. Mundy,et al.  Comparative study of available medical therapy for hypercalcemia of malignancy. , 1983, American Journal of Medicine.

[363]  J. Foley,et al.  Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53. , 1996, Cancer research.

[364]  R. Derynck,et al.  Actions of growth factors on plasma calcium. Epidermal growth factor and human transforming growth factor-alpha cause elevation of plasma calcium in mice. , 1986, The Journal of clinical investigation.

[365]  A. Sasaki,et al.  Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. (口答発表) , 1994 .

[366]  T Shinozaki,et al.  Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. , 1996, Cancer research.

[367]  T. Bringman,et al.  Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors , 1986, Nature.

[368]  C. Polychronakos,et al.  Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. , 1992, Anticancer research.

[369]  B. Segre,et al.  Metabolism of radioiodinated bovine parathyroid hormone in the rat. , 1976, Endocrinology.

[370]  P. Ritch,et al.  Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[371]  Brennan,et al.  Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.

[372]  Larry A. Nathanson,et al.  Case 29-1972 , 1972 .

[373]  G. Murphy,et al.  The second Stanford conference on International Standardization of prostate specific antigen assays , 1995, Cancer.

[374]  J. Jowsey,et al.  Hypophosphatemic osteomalacia associated with "nonendocrine" tumors. , 1970, The New England journal of medicine.

[375]  S. Pearce,et al.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. , 1995, The Journal of clinical investigation.

[376]  G. Hendy,et al.  A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. , 1992, The Journal of clinical endocrinology and metabolism.

[377]  J. Markham,et al.  Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. , 1975, The Journal of clinical investigation.

[378]  H. Gharib,et al.  Parathyroid hormone-related protein and hypercalcemia secondary to massive mammary hyperplasia. , 1990 .

[379]  原田 浩徳.  Phenotypic difference of normal plasma cells from mature myeloma cells , 1993 .

[380]  R. Toto,et al.  Long-term control of plasma calcitriol concentration in dogs and humans. Dominant role of plasma calcium concentration in experimental hyperparathyroidism. , 1985, The Journal of clinical investigation.

[381]  J. Lorente,et al.  Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. , 1996, The Journal of urology.

[382]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[383]  T. Yoneda,et al.  E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. , 1996, Cancer research.

[384]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[385]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[386]  B. Katzenellenbogen,et al.  Alterations in Transforming Growth Factor-α and -β Production and Cell Responsiveness during the Progression of MCF-7 Human Breast Cancer Cells to Estrogen-Autonomous Growth , 1994 .

[387]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[388]  T. Matise,et al.  Preliminary Localization of a Gene for Autosomal Dominant Hypoparathyroidism to Chromosome 3ql3 , 1994, Pediatric Research.

[389]  T. Martin,et al.  C8, a new member of the convertase family , 1996 .

[390]  G. Woods,et al.  Diffuse bony metastases at presentation in a child with glioblastoma multiforme: A case report , 1990, Cancer.

[391]  K. Yoshimoto,et al.  Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. , 1989, The Journal of clinical endocrinology and metabolism.

[392]  Yukiko Ozawa,et al.  An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. , 1996, Cancer research.

[393]  T. Martin,et al.  Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. , 1996, Endocrinology.

[394]  S. Wimalawansa.  Significance of plasma PTH‐rp in patients with hypercalcemia of malignancy treated with bisphosphonate , 1994, Cancer.

[395]  B. Klein,et al.  The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma , 1992, International journal of clinical & laboratory research.

[396]  J. Hermans,et al.  REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT , 1987, The Lancet.

[397]  G. Strewler,et al.  Hypercalcemia in malignancy. , 1990, The Western journal of medicine.

[398]  G. Mundy,et al.  In vivo effects of human recombinant transforming growth factor β on bone turnover in normal mice , 1990 .

[399]  A. Mithal,et al.  Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. , 1995, Endocrinology.

[400]  G. Roodman,et al.  Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. , 1995, The Journal of clinical investigation.

[401]  A. Norman,et al.  Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. , 1981, The New England journal of medicine.

[402]  M. Nobuyoshi,et al.  Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptides. , 1994, Biochemical and biophysical research communications.

[403]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[404]  M. Laakso,et al.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma , 1992, The Lancet.

[405]  B. Lanske,et al.  PTH/PTHrP Receptor in Early Development and Indian Hedgehog--Regulated Bone Growth , 1996, Science.

[406]  S. Takeda,et al.  Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. , 1996, The Journal of clinical endocrinology and metabolism.

[407]  J. Hayman,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.

[408]  M. Sporn,et al.  Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro , 1987, The Journal of cell biology.

[409]  M. Ogawa,et al.  Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. , 1993, Cancer research.

[410]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[411]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[412]  D. Drucker,et al.  Parathyroid hormone-like peptide shares features with members of the early response gene family: rapid induction by serum, growth factors, and cycloheximide. , 1992, Cancer research.

[413]  A. F. Stewart,et al.  Parathyroid Hormone-Related Protein as a Cardiovascular Regulatory Peptide* , 2001 .

[414]  A. Jasek,et al.  Acute spontaneous tumor lysis syndrome , 1994, American journal of hematology.

[415]  J. Wysolmerski,et al.  Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. , 1994, Annual review of medicine.

[416]  P. Kostenuik,et al.  Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. , 1996, Clinical & experimental metastasis.

[417]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[418]  T. Martin,et al.  Parathyroid hormone-related protein: biochemistry and molecular biology. , 1991, Critical reviews in biochemistry and molecular biology.

[419]  O. Niwa,et al.  Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells , 1993 .

[420]  Parfitt Am.  The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. , 1976 .

[421]  R. Nissenson,et al.  The parathyroid hormone-related protein as a regulator of normal tissue functions , 1994 .

[422]  J. Ratcliffe,et al.  Parathyroid hormone related protein and hypercalcaemia in breast cancer. , 1991, BMJ.

[423]  T. Guise,et al.  Physiological and pathological roles of parathyroid hormone-related peptide. , 1996, Current opinion in nephrology and hypertension.

[424]  J. Gold,et al.  Adoptive chemoimmunotherapy using Ex vivo activated memory T‐cells and cyclophosphamide: Tumor lysis syndrome of a metastatic soft tissue sarcoma , 1993, American journal of hematology.

[425]  J. Oesterling,et al.  Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. , 1995, Urology.

[426]  B. Zetter,et al.  Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. , 1989, The Journal of clinical investigation.

[427]  R. Baggs,et al.  A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.

[428]  M. Thiede.  The mRNA encoding a parathyroid hormone-like peptide is produced in mammary tissue in response to elevations in serum prolactin. , 1989, Molecular endocrinology.

[429]  K. Aoki,et al.  Humoral Hypercalcemia of Malignancy with Elevated Plasma PTHrP, TNFα and IL‐6 in Cutaneous Squamous Cell Carcinoma , 1996, The Journal of dermatology.

[430]  G. Roodman,et al.  Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. , 1989, Endocrinology.

[431]  J Glowacki,et al.  Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. , 1994, Genes & development.

[432]  A. Tashjian,et al.  Evidence for parathyroid hormone in nonparathyroid tumors associated with hypercalcemia. , 1965, Cancer research.

[433]  G. Mundy,et al.  Use of an in vivo model to determine the effects of interleukin‐1 on cells at different stages in the osteoclast lineage , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[434]  M. Koutsilieris,et al.  Skeletal metastases in advanced prostate cancer: cell biology and therapy. , 1995, Critical reviews in oncology/hematology.

[435]  M. Peaker,et al.  Production of parathyroid hormone-related protein by the mammary gland of the goat. , 1992, The Journal of endocrinology.

[436]  T. Martin,et al.  PC8 [corrected], a new member of the convertase family. , 1996, The Biochemical journal.

[437]  A. F. Stewart,et al.  Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types. , 1992, The Journal of biological chemistry.

[438]  G. Mundy,et al.  Effects of interleukin-1 on bone turnover in normal mice. , 1989, Endocrinology.

[439]  T. Rosol,et al.  Quantitative bone histomorphometry in nude mice bearing a human squamous cell lung cancer , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[440]  J. Kanis,et al.  Effects of intravenous etidronate disodium on skeletal and calcium metabolism. , 1987, The American journal of medicine.

[441]  J. Wozney,et al.  Transforming Growth Factor-β Gene Family Members and Bone* , 1994 .

[442]  T. Martin,et al.  Hypercalcemia in pregnancy and lactation due to parathyroid hormone-related protein production , 1990 .

[443]  K. Miyazono,et al.  Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. , 1993, Cancer research.

[444]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[445]  E. Kohn,et al.  Cancer invasion and metastases. , 1990, JAMA.

[446]  M E Doerr,et al.  The Roles of Integrins and Extracellular Matrix Proteins in the Insulin-like Growth Factor I-stimulated Chemotaxis of Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[447]  D. Klein,et al.  Prostaglandins: stimulation of bone resorption in tissue culture. , 1970, Endocrinology.

[448]  B. Lanske,et al.  Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[449]  E. Scanziani,et al.  Bone invasion by Walker 256 carcinoma, line A in young and adult rats: effects of etidronate. , 1990, Oncology.

[450]  J. Seidman,et al.  Calcium-ion-sensing cell-surface receptors. , 1995, The New England journal of medicine.

[451]  R. Rizzoli,et al.  Regulation of parathyroid hormone-related protein production in a human lung squamous cell carcinoma line. , 1994, The Journal of endocrinology.

[452]  T. Rosol,et al.  Effects of infusion of human parathyroid hormone‐related protein‐(1–40) in nude mice: Histomorphometric and biochemical investigations , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[453]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[454]  M. Thiede,et al.  In vivo regulation of parathyroid hormone-related peptide messenger ribonucleic acid in the rat uterus by 17 beta-estradiol. , 1991, Endocrinology.

[455]  T. Martin,et al.  Parathyroid hormone‐related protein in hypercalcaemia associated with haematological malignancy , 1996, British journal of haematology.

[456]  P. Kostenuik,et al.  Tumor-bone interactions in skeletal metastasis. , 1995, Clinical orthopaedics and related research.

[457]  J. Orloff,et al.  Further evidence for a novel receptor for amino-terminal parathyroid hormone-related protein on keratinocytes and squamous carcinoma cell lines. , 1995, Endocrinology.

[458]  D. Hosking,et al.  Rehydration in the treatment of severe hypercalcaemia. , 1981, The Quarterly journal of medicine.

[459]  S. Rabbani,et al.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.

[460]  P. Vihko,et al.  Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. , 1992, Endocrinology.

[461]  H. Lepor,et al.  Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. , 1993, The Journal of urology.